Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia

J Clin Oncol. 2006 Nov 20;24(33):e51-2. doi: 10.1200/JCO.2006.08.9128.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antineoplastic Agents / therapeutic use*
  • Blast Crisis / drug therapy
  • Blast Crisis / genetics
  • Clinical Trials, Phase II as Topic
  • Dasatinib
  • Disease Progression
  • Drug Resistance, Neoplasm*
  • Female
  • Genes, abl*
  • Humans
  • Leucine
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
  • Male
  • Middle Aged
  • Mutation*
  • Phenylalanine
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • Protein Kinase Inhibitors / therapeutic use
  • Pyrimidines / therapeutic use*
  • Thiazoles / therapeutic use*
  • Treatment Failure

Substances

  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Thiazoles
  • Phenylalanine
  • Leucine
  • Dasatinib